A study evaluated the immunogenicity of a vaccine based on MUC1 in patients without CRC cancer but with advanced colonic adenomas (precursors of CRC) and showed high levels of anti-MUC1 IgG along with long-lasting immune memory in 44% of these individuals (161). The gene discussed is MUC1; the disease is colon adenoma.